---
category: news
title: "Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice"
excerpt: "Ruxolitinib is the first janus kinase 1 (JAK1) and JAK2 inhibitor that was approved by the United States Food and Drug Administration (FDA) agency for the treatment of myeloproliferative neoplasms. The drug targets the JAK/STAT signalling pathway,"
publishedDateTime: 2021-02-15T11:03:00Z
originalUrl: "https://www.nature.com/articles/s41598-021-83222-z"
webUrl: "https://www.nature.com/articles/s41598-021-83222-z"
type: article
quality: 0
heat: 0
published: false

provider:
  name: Nature
  domain: nature.com

topics:
  - Computer Vision
  - AI

images:
  - url: "https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-021-83222-z/MediaObjects/41598_2021_83222_Fig1_HTML.png"
    width: 623
    height: 685
    isCached: true

secured: "tiJb7ML2OTTMfVYFQL350BCYvQi3GzP1pBvP6BpbqudgQfj0f4Gk0iuCKm1/o+Ju0dLkzK4/ZVlKNgW3R+c0ktII4T1lA0FXXp9DymsUmNdfQdz7YbPAQtQTB52Yn327uGtbnoArQfeEV3FnE8BwV1fLYDFjbMngeleIWEwXw2XRS+H5mWEmTBCwZKcszh5kcLGr6UEyGvd0shepS3u/TZS3SddXQT1+DyPnWv+5ozrhqngQck6PDpFtRjqC8rIEsTw4pXmmCzDFZR0ntbHYuxNe9ZNdDq006JeVD1kSpKVftfHH2nds//TqqUw1Ze591SRDgEYTMyp0aM9M+8GPLnOAyb+mOH3qmWkPJ9NVCws=;mR2FfdlXciX+Y70NSTSWxQ=="
---

